The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
Open accessAbstract
OBJECTIVE: To investigate pharmacokinetic and pharmacodynamic factors associated with population differences in warfarin doses needed to achieve anticoagulation, in particular the possible involvement of genetic variability in vitamin K epoxide reductase (VKOR) and CYP2C9. METHODS: Warfarin maintenance dose, unbound plasma S-warfarin concentration [Cu(S)] and INR were determined in 157 Caucasians, 172 Japanese, and 36 African-Americans stably anticoagulated patients. In a subset (n = 166), fully carboxylated plasma normal prothrombin levels (NPT) were also measured. Genotyping for seven CYP2C9 (CYP2C9*1 through 6 and *11) and seven VKORC1 variants were performed in 115 Caucasians and 64 Japanese patients and 66 healthy African-Americans. Multivariate analysis was performed to identify covariates associated with warfarin requirement. RESULTS: The relationship between NPT and Cu(S) indicated Japanese are more susceptible to inhibition of NPT production by S-warfarin than the other two populations. VKORC1 1173 C > T had a greater frequency in Japanese (89.1%) than Caucasians (42.2%) and African-Americans (8.6%). CYP2C9 variants with reduced metabolizing ability were less frequent in Japanese compared to the other two populations. The median warfarin dose was significantly higher in Caucasians than Japanese patients (5.5 versus 3.5 mg/day), however, when matched for CYP2C9*1 homozygosity, no difference in dose was observed between VKORC1 genotype-matched groups. Furthermore, VKORC1 1173C > T and CYP2C9 (*2/*3/*11) genotypes, age and weight were identified as independent covariates contributing to interpatient variability in warfarin dosage. CONCLUSIONS: Both VKORC1 and CYP2C9 polymorphisms contribute to inter-population difference in warfarin doses among the three populations, but their contribution to intra-population variability may differ within each population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Due to genetic differences in pharmacokinetics and pharmacodynamics, clopidogrel [29], phenytoin [30], warfarin [31], clozapine [32], and carbamazepine [33] also had variable efficacy and side-effect profiles in Western and non-Western individuals.”
From Hasty generalizations and generics in medical research: A systematic review (2024) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H. I., Jacobson, A. K., & Hylek, E. M. (2004) · CHEST Journal · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,530
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,391
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,239
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Rost, S., Fregin, A., Ivaškevičius, V., Conzelmann, E., Hörtnagel, K., Pelz, H., Lappegård, K. T., Seifried, E., Scharrer, I., Tuddenham, E. G. D., et al. (2004) · Nature · doi:10.1038/nature02214 · Cited by 1,152
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,052
D’Andrea, G., D’Ambrosio, R., Perna, P. D., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E., & Margaglione, M. (2004) · Blood · doi:10.1182/blood-2004-06-2111 · Cited by 696
Yuan, H., Chen, J., Lee, M. T. M., Wung, J., Chen, Y., Charng, M., Lu, M.-J., Hung, C., Wei, C.-Y., Chen, C.-H., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi180 · Cited by 484
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S. E., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D. R., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500313 · Cited by 462
Bodin, L. (2005) · Blood · doi:10.1182/blood-2005-01-0341 · Cited by 360
Scordo, M. G. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129321 · Cited by 344
Self-citation
Cited by
Sorted by citations
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
The International Warfarin Pharmacogenetics Consortium (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,573
Anderson, J. L., Horne, B. D., Stevens, S. M., Grove, A. S., Barton, S., Nicholas, Z. P., Kahn, S. F. S., May, H. T., Samuelson, K. M., Muhlestein, J. B., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.737312 · Cited by 723
Pena, S. D. J., Pietro, G. D., Fuchshuber-Moraes, M., Genro, J. P., Hutz, M. H., Kehdy, F. S. G., Kohlrausch, F. B., Magno, L. A. V., Montenegro, R. C., de Moraes, M. O., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017063 · Cited by 678
Shen, A. Y., Yao, J. F., Brar, S. S., Jorgensen, M. B., & Chen, W. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.098 · Cited by 657
Genetic Determinants of Response to Warfarin during Initial Anticoagulation
Schwarz, U. I., Ritchie, M. D., Bradford, Y., Li, C., DUDEK, S. M., Frye-Anderson, A., Kim, R. B., Roden, D. M., & Stein, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708078 · Cited by 572
Self-citationThe largest prospective warfarin-treated cohort supports genetic forecasting
Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R. E., Rane, A., & Deloukas, P. (2008) · Blood · doi:10.1182/blood-2008-04-149070 · Cited by 548
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Association of warfarin dose with genes involved in its action and metabolism
Wadelius, M., Chen, L. Y., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., Bentley, D., McGinnis, R. E., & Deloukas, P. (2006) · Human Genetics · doi:10.1007/s00439-006-0260-8 · Cited by 386
Massively Parallel Sequencing: The Next Big Thing in Genetic Medicine
Tucker, T., Marra, M. A., & Friedman, J. M. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.06.022 · Cited by 393
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
Limdi, N. A., Wadelius, M., Cavallari, L. H., Eriksson, N., Crawford, D. C., Lee, M. T. M., Chen, C.-H., Motsinger‐Reif, A. A., Sagreiya, H., Liu, N., et al. (2010) · Blood · doi:10.1182/blood-2009-12-255992 · Cited by 374
Pharmacogenetics of warfarin: current status and future challenges
Wadelius, M., & Pirmohamed, M. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500417 · Cited by 333
Booven, D. V., Marsh, S., McLeod, H. L., Whirl‐Carrillo, M., Sangkuhl, K., Klein, T. E., & Altman, R. B. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283349e84 · Cited by 241
Wang, K.-L., Lip, G. Y. H., Lin, S., & Chiang, C. (2015) · Stroke · doi:10.1161/strokeaha.115.009947 · Cited by 237
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 — Rationale and perspectives
Yin, T., & Miyata, T. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2006.10.021 · Cited by 226
Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis
Lindh, J. D., Holm, L., Andersson, M. L., & Rane, A. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0584-5 · Cited by 216
Ethnic Differences in Cardiovascular Drug Response
Johnson, J. A. (2008) · Circulation · doi:10.1161/circulationaha.107.704023 · Cited by 212
Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans
Cavallari, L. H., Langaee, T. Y., Momary, K. M., Shapiro, N. L., Nutescu, E. A., Coty, W. A., Viana, M. A. G., Patel, S., & Johnson, J. A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.223 · Cited by 196
Self-citationEstimation of Warfarin Maintenance Dose Based on VKORC1 (−1639 G>A) and CYP2C9 Genotypes
Zhu, Y., Shennan, M. G., Reynolds, K. K., Johnson, N. A., Herrnberger, M. R., Valdes, R., & Linder, M. W. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.078139 · Cited by 183
Genetic-based dosing in orthopedic patients beginning warfarin therapy
Millican, E. A., Lenzini, P. A., Milligan, P. E., Grosso, L., Eby, C., Deych, E., Grice, G. R., Clohisy, J. C. F., Barrack, R. L., Burnett, R. S. J., et al. (2007) · Blood · doi:10.1182/blood-2007-01-069609 · Cited by 176
Ia, T. A. D. A. F. C., reviews, S., Ib, M.-A. C., IIa, R. C. T. C., IIb, N.-R. C. T. C., class, O. Q.-E. S., III, studies, N.-E. R. (., studies, C., class, C. S. A., IV, & authorities., O. O. C. O. E. A. (2014) · Pediatrics International · doi:10.1111/ped.12317 · Cited by 172
Jorgensen, A., FitzGerald, R. J., Oyee, J., Pirmohamed, M., & Williamson, P. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044064 · Cited by 169
A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance
Loebstein, R., Dvoskin, I., Halkin, H., Vecsler, M., Lubetsky, A., Rechavi, G., Amariglio, N., Cohen, Y., Ken‐Dror, G., Almog, S., et al. (2006) · Blood · doi:10.1182/blood-2006-08-038984 · Cited by 169
Kimura, R., Miyashita, K., Kokubo, Y., Akaiwa, Y., Otsubo, R., Nagatsuka, K., Otsuki, T., Okayama, A., Minematsu, K., Naritomi, H., et al. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2006.09.007 · Cited by 167
Verhoef, T. I., Redekop, K., Daly, A. K., van Schie, R. M., de Boer, A., & der Zee, A. H. M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12220 · Cited by 165
Combined CYP2C9 , VKORC1 and CYP4F2 Frequencies among Racial and Ethnic Groups
Scott, S. A., Khasawneh, R. H., Peter, I., Kornreich, R., & Desnick, R. J. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.49 · Cited by 162
Limdi, N. A., Arnett, D. K., Goldstein, J. A., Beasley, T. M., McGwin, G., Adler, B. K., & Acton, R. T. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.511 · Cited by 160
Tham, L. S., Goh, B. C., Nafziger, A. N., GUO, J., WANG, L., Soong, R., & Lee, S. M. L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.009 · Cited by 148
Prospective Study of Warfarin Dosage Requirements Based on CYP2C9 and VKORC1 Genotypes
Wen, M.-S., Lee, M., Chen, J.-J., Chuang, H.-P., Lu, L.-S., Chen, C.-H., Lee, T.-H., Kuo, C.-T., Sun, F.-M., Chang, Y.-J., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100453 · Cited by 142
Hamberg, A., Dahl, M.-L., Barban, M., Scordo, M. G., Wadelius, M., Pengo, V., Padrini, R., & Jonsson, E. N. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100084 · Cited by 141
Self-citationGenetic and clinical factors relating to warfarin dosing
Jonas, D. E., & McLeod, H. L. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.05.001 · Cited by 133
Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian Patients
Perini, J. A., Struchiner, C. J., Silva-Assunção, E., Santana, I., Rangel, F., Ojopi, E. P. B., Dias‐Neto, E., & Suarez‐Kurtz, G. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.166 · Cited by 132
Cha, P.-C., Mushiroda, T., Takahashi, A., Kubo, M., Minami, S., Kamatani, N., & Nakamura, Y. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq389 · Cited by 132
Limdi, N. A., & Veenstra, D. L. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.9.1084 · Cited by 124
Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans
Schelleman, H., Chen, J., Chen, Z., Christie, J. D., Newcomb, C., Brensinger, C. M., Price, M., Whitehead, A., Kealey, C., Thorn, C. F., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.101 · Cited by 119
Pharmacogenetics of Oral Anticoagulants
Stehle, S., Kirchheiner, J., Lazar, A., & Fuhr, U. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847090-00002 · Cited by 113
Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin
Kangelaris, K. N., Bent, S., Nussbaum, R. L., Garcia, D. A., & Tice, J. A. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-0949-1 · Cited by 112
Limdi, N. A., Beasley, T. M., Crowley, M. R., Goldstein, J. A., Rieder, M. J., Flockhart, D. A., Arnett, D. K., Acton, R. T., & Liu, N. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.10.1445 · Cited by 112
Understanding and applying pharmacometric modelling and simulation in clinical practice and research
Standing, J. F. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13119 · Cited by 115
Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians
Schelleman, H., Chen, Z., Kealey, C., Whitehead, A. S., Christie, J. D., Price, M., Brensinger, C. M., Newcomb, C. W., Thorn, C. F., Samaha, F. F., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100144 · Cited by 109
Pharmacogenetics in Cardiovascular Antithrombotic Therapy
Marín, F. R., Gónzález‐Conejero, R., Capranzano, P., Bass, T. A., Roldán, V., & Angiolillo, D. J. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.084 · Cited by 105
CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic Dosing
Scott, S. A., Jaremko, M., Lubitz, S. A., Kornreich, R., Halperin, J. L., & Desnick, R. J. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.71 · Cited by 100
Yang, J., Chen, Y., Li, X., Wei, X., Chen, X., Zhang, L., Zhang, Y., Xu, Q., Wang, H., Li, Y., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.151 · Cited by 94
Venous thromboembolism and ethnicity
Roberts, L. N., Patel, R., & Arya, R. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07786.x · Cited by 94
Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans
Kimmel, S. E., Christie, J. D., Kealey, C., Chen, Z., Price, M., Thorn, C. F., Brensinger, C. M., Newcomb, C. W., & Whitehead, A. S. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500445 · Cited by 87
Shen, A. Y., Yao, J. F., Brar, S. S., Jorgensen, M. B., Wang, X., & Chen, W. (2008) · Stroke · doi:10.1161/strokeaha.107.508580 · Cited by 86
Paxton, J. W. (2012) · InTech eBooks · doi:10.5772/1180 · Cited by 90
Ross, K., Bigham, A. W., Edwards, M., Gozdzik, A., Suarez‐Kurtz, G., & Parra, E. J. (2010) · Journal of Human Genetics · doi:10.1038/jhg.2010.73 · Cited by 87
McClain, M. R., Palomaki, G. E., Piper, M., & Haddow, J. E. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e31815bf924 · Cited by 80
Warfarin therapy: in need of improvement after all these years
Kimmel, S. E. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.5.677 · Cited by 80
Impact of race and gender on antithrombotic therapy
Capodanno, D., & Angiolillo, D. J. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-04-0232 · Cited by 79
Factors Influencing Warfarin Dose Requirements in African–Americans
Momary, K. M., Shapiro, N. L., Viana, M. A. G., Nutescu, E. A., Helgason, C. M., & Cavallari, L. H. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.11.1535 · Cited by 76
Self-citationShaw, K., Amstutz, U., Kim, R. B., Lesko, L. J., Turgeon, J., Michaud, V., Hwang, S., Ito, S., Ross, C. J., & Carleton, B. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000192 · Cited by 76
Pharmacogenetics: from discovery to patient care
Shin, J., Kayser, S. R., & Langaee, T. Y. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080170 · Cited by 72
Personalized medicine: hope or hype?
Salari, K., Watkins, H. C., & Ashley, E. A. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs112 · Cited by 76
Pharmacogenomics — Ready for Prime Time?
Shurin, S. B., & Nabel, E. G. (2008) · New England Journal of Medicine · doi:10.1056/nejme0800801 · Cited by 70
Zambon, C., Pengo, V., Padrini, R., Basso, D., Schiavon, S., Fogar, P., Nisi, A., Frigo, A. C., Moz, S., Pelloso, M., et al. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.162 · Cited by 63
Self-citationRole of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants
Cavallari, L. H., Shin, J., & Perera, M. A. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.1192 · Cited by 62
Liang, R., Li, L., Li, C., Gao, Y., Liu, W., Hu, D., & Sun, Y. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0725-7 · Cited by 62
Roper, N., Storer, B. E., Bona, R., & Fang, M. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090110 · Cited by 62
Influence of CYP4F2 genotype on warfarin dose requirement–a systematic review and meta-analysis
Liang, R., Wang, C., Zhao, H., Huang, J., Hu, D., & Sun, Y. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.11.043 · Cited by 61
Borgiani, P., Ciccacci, C., Forte, V., Romano, S., Federici, G., & Novelli, G. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.11.1545 · Cited by 61
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population
Lubitz, S. A., Scott, S. A., Rothlauf, E. B., AGARWAL, A., Peter, I., Doheny, D. O., van der Zee, S. A., Jaremko, M., YOO, C., Desnick, R. J., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03792.x · Cited by 61
Yoshizawa, M., Hayashi, H., Tashiro, Y., Sakawa, S., Moriwaki, H., Akimoto, T., Doi, O., Kimura, M., Kawarasaki, Y., Inoue, K., et al. (2009) · Thrombosis Research · doi:10.1016/j.thromres.2008.11.011 · Cited by 59
Cho, H.-J., Sohn, K., Park, H.-M., Lee, K., Choi, B., Kim, S., Kim, J. S., On, Y., Chun, M., Kim, H., et al. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.4.329 · Cited by 59
Racial and Ethnic Disparities in Adverse Drug Events: A Systematic Review of the Literature
Baehr, A., Peña, J. C., & Hu, D. J. (2015) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-015-0101-3 · Cited by 58
Osman, A., Enström, C., Arbring, K., Söderkvist, P., & Lindahl, T. L. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02039.x · Cited by 57
Oral anticoagulants: Pharmacogenetics
D’Andrea, G., D’Ambrosio, R., & Margaglione, M. (2008) · Blood Reviews · doi:10.1016/j.blre.2007.11.004 · Cited by 56
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy
Limdi, N. A., Wiener, H. W., Goldstein, J. A., Acton, R. T., & Beasley, T. M. (2009) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2009.01.019 · Cited by 56
VKORC1 and CYP2C9 genotype distribution in Asian countries
Gaikwad, T., Ghosh, K., & Shetty, S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.05.028 · Cited by 56
Namazi, S., Azarpira, N., Hendijani, F., Banan, M., Vessal, G., & Mehdipour, A. R. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.06.010 · Cited by 55
Ethnic Differences in Warfarin Maintenance dose Requirement and its Relationship with Genetics
Schelleman, H., Limdi, N. A., & Kimmel, S. E. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.9.1331 · Cited by 55
Michaud, V., Vanier, M.-C., Brouillette, D., Roy, D., Verret, L., Nathaniel Birdling, N. O. E. L., Taillon, I., O’Hara, G. E., Gossard, D., Champagne, M. J., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100434 · Cited by 53
The impact of body weight on rivaroxaban pharmacokinetics
Barsam, S. J., Patel, J. P., Roberts, L. N., Kavarthapu, V., Patel, R., Green, B., & Arya, R. (2017) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12039 · Cited by 52
Validation of Clinical Testing for Warfarin Sensitivity
Langley, M. R., Booker, J. K., Evans, J. P., McLeod, H. L., & Weck, K. E. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080123 · Cited by 51
Ueshima, S., Hira, D., Kimura, Y., Fujii, R., Tomitsuka, C., Yamane, T., Tabuchi, Y., Ozawa, T., Itoh, H., Ohno, S., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13561 · Cited by 50
Özer, N., Çam, N., Tangürek, B., Ozer, S., Uyarel, H., Öz, D., Güney, M., & Çiloğlu, F. (2010) · Heart and Vessels · doi:10.1007/s00380-009-1177-7 · Cited by 49
Gan, G. G., Phipps, M. E., Lee, M. M. T., Lü, L., Subramaniam, R. Y., Bee, P. C., & Chang, S. H. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1119-6 · Cited by 48
Pharmacogenomics of warfarin: Uncovering a piece of the warfarin mystery
Gulseth, M. P., Grice, G. R., & Dager, W. E. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080127 · Cited by 48
Effect of Race/Ethnicity on the Efficacy of Warfarin
Shen, A. Y., Chen, W., Yao, J. F., Brar, S. S., Wang, X., & Go, A. S. (2008) · CNS Drugs · doi:10.2165/00023210-200822100-00003 · Cited by 47
Warfarin–Antiretroviral Interactions
Liedtke, M. D., & Rathbun, R. C. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l497 · Cited by 47
Ko, D., Cove, C. L., & Hylek, E. M. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-12-1032 · Cited by 46
Manji, I., Pastakia, S. D., DO, A. N., Ouma, M., Schellhase, E. M., Karwa, R., Miller, M. L., Saina, C., & Akwanalo, C. O. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04503.x · Cited by 46
VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals
Aklillu, E., Leong, C., Loebstein, R., Halkin, H., & Gak, E. (2008) · Blood · doi:10.1182/blood-2008-01-135863 · Cited by 46
Effect of the VKORC1 Genotype on Warfarin Dose Requirements in Japanese Pediatric Patients
Kato, Y., Ichida, F., Saito, K., Watanabe, K., Hirono, K., Miyawaki, T., Yoshimura, N., Horiuchi, I., Taguchi, M., & Hashimoto, Y. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-nt-082 · Cited by 44
Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Polymorphism and Aortic Calcification
Teichert, M., Visser, L., van Schaik, R. H. N., Hofman, A., Uitterlinden, A. G., Smet, P. A. G. M. D., Witteman, J. C. M., & Stricker, B. H. C. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.159913 · Cited by 44
Pharmacogenomics of warfarin in populations of A frican descent
Suarez‐Kurtz, G., & Botton, M. R. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04354.x · Cited by 43
Fluorescence enhancement of warfarin induced by interaction with β‐cyclodextrin
Vasquez, J. M., Vu, A., Schultz, J. S., & Vullev, V. I. (2009) · Biotechnology Progress · doi:10.1002/btpr.188 · Cited by 43
Kimura, R., Kokubo, Y., Miyashita, K., Otsubo, R., Nagatsuka, K., Otsuki, T., Sakata, T., Nagura, J., Okayama, A., Minematsu, K., et al. (2006) · International Journal of Hematology · doi:10.1532/ijh97.06082 · Cited by 43
Saraeva, R., Paskaleva, I., Doncheva, E., Eap, C. B., & Ganev, V. S. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00870.x · Cited by 41
Genome-wide sequence analyses of ethnic populations across Russia
Zhernakova, D. V., Brukhin, V. B., Malov, S. V., Oleksyk, T. K., Koepfli, K., Zhuk, A. S., Dobrynin, P. V., Kliver, S. F., Cherkasov, N., Tamazian, G., et al. (2019) · Genomics · doi:10.1016/j.ygeno.2019.03.007 · Cited by 40
Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy
Katz, D. A., Murray, B. P., Bhathena, A., & Sahelijo, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2486 · Cited by 41
Gu, Q., Kong, Y., Schneede, J., Xiao, Y., Chen, L., Zhong, Q., Xue-feng, W., Hao, J., Chen, B., & Chen, J.-J. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0863-9 · Cited by 40
Cho, H.-J., On, Y., Bang, O. Y., Kim, J., Huh, W., Ko, J., Kim, J. S., & Lee, S. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.004 · Cited by 39
Lima, M. V. R., Ribeiro, G. S., Mesquita, E. T., Victer, P. R., & Vianna‐Jorge, R. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0385-2 · Cited by 39
Bazan, N. S., Sabry, N. A., Rizk, A., Mokhtar, S., & Badary, O. A. (2013) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-013-0978-y · Cited by 38
The association of protein S Tokushima-K196E with a risk of deep vein thrombosis
Ikejiri, M., Wada, H., Sakamoto, Y., Ito, N., Nishioka, J., Nakatani, K., Tsuji, A., Yamada, N., Nakamura, M., Ito, M., et al. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0671-0 · Cited by 38
Pharmacogenetics of vitamin K antagonists: useful or hype?
Lippi, G., Franchini, M., & Favaloro, E. J. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.140 · Cited by 38
Spreafico, M., Lodigiani, C., van Leeuwen, Y., Pizzotti, D., Rota, L. L., Rosendaal, F. R., Mannucci, P. M., & Peyvandi, F. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.9.1237 · Cited by 38
Kim, J. H., Kim, G. S., Kim, E. J., Park, S., Chung, N., & Chu, S. H. (2011) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0b013e31820914e7 · Cited by 37
Role of cytochrome P450 genotype in the steps toward personalized drug therapy
Cavallari, L. H., Jeong, & Bress, A. P. (2011) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s15497 · Cited by 39
Metadata
- Authors
- Takahashi, H., Wilkinson, G. R., Nutescu, E. A., Morita, T., Ritchie, M. D., Scordo, M. G., Pengo, V., Barban, M., Padrini, R., Ieiri, I., Otsubo, K., Kashima, T., Kimura, S., Kijima, S., & Echizen, H.
- Affiliations
- Meiji Pharmaceutical University (JP)
- University of Illinois Chicago (US)
- Vanderbilt University (US)
- University of Messina (IT)
- University of Padua (IT)
- Tottori University (JP)
- Eisai (Japan) (JP)
- Corresponding author
- Takahashi, Harumi
- ORCID
- Venue
- Pharmacogenetics and Genomics
- Published
- 2006-02
- Volume
- 16
- Issue
- 2
- Pages
- 101-110
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2042292509
- Cited by
- 376
- References
- 31
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 10 · 2019: 17 · 2018: 9 · 2017: 14 · 2016: 16 · 2015: 16 · 2014: 28 · 2013: 25 · 2012: 25
- FWCI
- 38.09
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Pharmacogenetics and Genomics (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Funders
- Eisai
- National Institutes of Health (GM31304)
- U.S. Public Health Service
- National Institute of General Medical Sciences (GM31304, P01GM031304)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Keywords
- warfarin, VKORC1, CYP2C9, genetic polymorphism, vitamin K epoxide reductase, interpopulation variability, Japanese, Caucasians, African Americans, S-warfarin, anticoagulation, pharmacogenetics
- MeSH terms
- Aryl Hydrocarbon Hydroxylases, Black or African American, Female, Genotype, Humans, Mixed Function Oxygenases, Infant, Japan, Male, Pharmacogenetics, United States, Genetic Variation, Warfarin, Black People, White People, Asian People, Vitamin K Epoxide Reductases, Cytochrome P-450 CYP2C9
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
